Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
AAM Sees Boon From Biden Order And CMS Biosimilar Action
US Generics And Biosimilars Industry Association Welcomes Latest Developments
Oct 20 2022
•
By
David Wallace
Biden’s executive order is aimed at lowering prescription drug costs • Source: Shutterstock
More from Policy & Regulation
More from Generics Bulletin